Global Irritable Bowel Syndrome with Constipation Drugs Market Size, Share, Growth, Industry Trends, Competitive Analysis and Forecast to 2030

Price: 3600/- USD |

The global irritable bowel syndrome with constipation (IBS-C) drugs market has been projected to grow at the CAGR of 6.3% market during 2020-2027. The IBS-C expected to show significant growth during the forecast period on account of increasing demand for IBS drugs globally, efficient pipeline molecules, modern dietary habits leads to develop IBS, rapid commercialization and regulatory approvals to the newer medication would influence the market growth of IBS-C drugs worldwide.

Market Insights:

The global irritable bowel syndrome with constipation IBS-C drugs market is anticipated to grow significantly during the forecast period due to increasing healthcare awareness and modern unhealthy dietary habits. It is observed that more than 10% of the global population is affected with IBS-C; however, it is more prevalent in females and in developed countries. It is observed that lubiprostone and linaclotide are the most widely used in the market for the treatment of IBS-C due to its proven efficiency and established safety profile. There are different promising drugs in the pipeline such as Plecanatide, Ibodutant, Tenapanor, Relenopride, and Lovastatin anticipated to drive market growth during forecast period. Currently, Europe is expected to be the largest regional market for IBS-C drugs followed by North America because the prevalence of IBS is more in developed economies, modern dietary habits, unhealthy work conditions and adoption of branded IBS-C drugs in developed economies are influencing the market growth. Significant unmet needs and increasing healthcare awareness would create significant opportunities for the market players in Asia Pacific regional market.

Market Segment Insights:

For the purpose of the study global IBS-C market is studied for drug type and prescription type. Pipeline drug analysis (Plecanatide, Ibodutant, Tenapanor, Relenopride, and Lovastatin), Lubiprostone, Linaclotide, Stimulant Laxatives, Osmotic Laxatives, and other marketed drugs are primarily considered in the drug segment. On the other hand, on the basis of the type of prescription market is segmented as prescribed drugs and over the counter drugs.

Global IBS-C Market Segmentation:

By Drug Type, 2018–2027 ($ Million)

  • Lubiprostone
  • Linaclotide
  • Stimulant Laxatives
    • Bisacodyl
    • Senna
  • Osmotic Laxatives
    • Lactulose
    • Polyethylene Glycol
  • Others (Psyllium) – Qualitative Information
  • Pipeline Drug Analysis: Plecanatide, Ibodutant, Tenapanor, Relenopride, Lovastatin

By Prescription Type, 2018–2027 ($ Million)

By Geography, 2018-2027 ($ Million)

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Regional Insights:

For the purpose of this study, the global IBS-C market is regionally categorized into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa markets. These regional markets are further sub-segmented into top country level markets that majorly determine the regional industry trends. Among the considered regional markets, Europe is currently dominates the global IBS-C drugs market followed by North America, with United Sates being the largest county-level market due to the higher prevalence of IBS, more patient compliance and preference for branded IBS-C drugs would drive the market growth of IBS-C drugs in Europe and North America. On the other hand, Asia Pacific is anticipated to be the fastest growing market for IBS-C drugs. Increasing healthcare awareness, improvement in economic conditions and limited treatment availability are the most prominent market drivers in Asia pacific.

Market Competition Assessment:

The major players currently operating in the global IBS-C drugs market include Abbott Laboratories, Ardelyx, Astellas Pharmaceuticals, Catalent Pharmaceuticals Solutions, Nestle, Novartis, Sucampo Pharmaceuticals, Synergy Pharmaceuticals and Synthetic Biologics, Inc.

List of Key Companies:

  • Abbott Laboratories
  • Ardelyx
  • Astellas Pharmaceuticals
  • Catalent Pharmaceuticals Solutions
  • Nestle
  • Novartis
  • Sucampo Pharmaceuticals
  • Synergy Pharmaceuticals
  • Synthetic Biologics, Inc.
  • Other Major Players

Request a free report sample @

Table of Content:

Chapter 1 Preface

1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary

2.1 Global IBS-C Market Portraiture
2.2 Global IBS-C Drugs Market, by Drug Type, 2019 ($ Million)
2.3 Global IBS-C Drugs Market, by Prescription Type, 2019 ($ Million)
2.4 Global IBS-C Drugs Market, by Geography, 2019 (Value %)

Chapter 3 Global IBS-C Drugs Market Analysis

3.1 Global IBS-C Drugs Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers Effective drugs in clinical pipeline Adverse health effects from modern dietary habits
3.2.2 Challenges Treatment unawareness in some countries Stringent regulatory guidelines
3.2.3 Opportunities High unmet needs
3.3 Attractive Investment Proposition, 2019
3.4 Competitive Landscape Assessment, by Key Market Players

Chapter 4 Global IBS-C Drugs Market Analysis, by Drug Type, 2018-2027 ($ Million)

4.1 Introduction
4.2 Lubiprostone
4.3 Linaclotide
4.4 Stimulant Laxatives
4.4.1 Bisacodyl
4.4.2 Senna
4.5 Osmotic Laxatives
4.5.1 Lactulose
4.5.2 Polyethylene Glycol
4.6 Others (Psyllium) – Qualitative Information
4.7 Pipeline Drug Analysis: Plecanatide, Ibodutant, Tenapanor, Relenopride, Lovastatin

Chapter 5 Global IBS-C Drugs Market Analysis, by Prescription Type 2018-2027 ($ Million)

5.1 Introduction
5.2 Prescribed Drugs
5.3 Over the Counter Drugs

Chapter 6 Global IBS-C Drugs Market, by Geography, 2018-2027 ($ Million)

6.1 Preface
6.2 North America (U.S. & Canada)
6.3 Europe (U.K., Germany & Rest of Europe)
6.4 Asia Pacific (China, Japan, and Rest of APAC)
6.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)

Chapter 7 Company Profiles

7.1 Abbott Laboratories
7.2 Ardelyx
7.3 Astellas Pharmaceuticals
7.4 Catalent Pharmaceuticals Solutions
7.5 Nestle
7.6 Novartis
7.7 Sucampo Pharmaceuticals
7.8 Synergy Pharmaceuticals
7.9 Synthetic Biologics, Inc.
7.10 Other Major Players
Fill the given form to inquiry before buying for Irritable Bowel Syndrome with Constipation Drugs Market Report

(Additional country analysis and conmapny analysis will be added according to the request, we provide free report customization)
(Report covers the impact of COVID-19 on the market)

Request Report Sample
Inquiry Before Buying
Schedule a Call

Select License Type
$ 3600/- Single User License
$ 4600/- Multi User License
$ 5995/- Corporate License

Paypal Certified Payment
For Any Assitance

Why To Choose Us:
  • Markets in over 100+ countries analyzed granularly
  • 35% of our total client are returning clients
  • 1000+ customers globally
  • 100+ paid data sources mined to bring cutting-edge insights
  • 24x5 availability - we are always there when you need us
  • "Free of Cost Report Customization" is available
  • Request a regional report at Best Price

Impacts of COVID-19
COVID-19 Impact on the Irritable Bowel Syndrome with Constipation Drugs Market

Get in Touch

For any coustomized project, contact us here:

Our Clients